Save Product
Product Details
Synonyms
Spike, S protein RBD, Spike glycoprotein Receptor-binding domain, S glycoprotein RBD, Spike protein RBD
Source
Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (SPD-C82Eh) is expressed from human 293 cells (HEK293). It contains AA Arg 319 - Lys 537 (Accession # QHD43416.1 (L452Q, F490S)). Mutations L452Q, F490S were identified in the SARS-CoV-2 Lambda variant (Pango lineage: C.37).
Predicted N-terminus: Arg 319
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 28.2 kDa. The protein migrates as 33-38 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Biotinylated SARS-CoV-2 Spike RBD (L452Q, F490S), His,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
SEC-MALS
The purity of Biotinylated SARS-CoV-2 Spike RBD (L452Q, F490S), His,Avitag (Cat. No. SPD-C82Eh) is more than 90% and the molecular weight of this protein is around 27-41 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (Cat. No. SPD-C82Eh) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human ACE2, Fc Tag (Cat. No. AC2-H5257) with a linear range of 0.1-3 ng/mL (QC tested).
Protocol
Immobilized Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (Cat. No. SPD-C82Eh) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) with a linear range of 0.1-2 ng/mL (Routinely tested).
Protocol
Immobilized Human ACE2, Fc Tag (Cat. No. AC2-H5257) at 5 μg/mL (100 μL/well) can bind Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (Cat. No. SPD-C82Eh) with a linear range of 2-156 ng/mL (Routinely tested).
Protocol
Immobilized Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (Cat. No. S1N-M122) at 1 μg/mL (100 μL/well) can bind Biotinylated SARS-CoV-2 Spike RBD, His,Avitag (Cat. No. SPD-C82Eh) with a linear range of 0.1-3 ng/mL (Routinely tested).
Protocol
Customer Reviews Writing Reviews
J***n2021-09-09
LikesThank you so much for being accommodating and sending the protein to us as fast a possible. We really needed this for an important experiment and I appreciate how well your customer service handled my order. The reply for the invoice went very smoothly as well due to receiving it the same day as the order. I will definitely look for supplies through your company in the future. Overall, I would give Acro Biosystems for my unique protein needs in the future. Thank you.
- B***y2021-09-01 LikesMy peptides arrived in a timely manner and I had no issues using them in my COVID assay. I would purchase again from ACRO due to their great product quality and customer service. The team was very helpful in answering any questions I had about the product and assured me if any issues did come about I could reach out anytime.
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
